Abstract 1672P
Background
Waiting involves staying in a place until an expected event occurs. From diagnosis to follow-up and treatment, cancer patients (pts) often endure waiting. Understanding their emotions during this time is crucial. Few studies have explored the experiences and emotions of cancer pts in the waiting room (WR).
Methods
An anonymous 12-item online questionnaire was distributed to cancer pts in our center's WR. The questionnaire was divided into 3 sections including clinical and socio-demographic information, time spent in the WR, and pts considerations. The aim of this study was to investigate cancer pts’ emotions and behaviors in the WR.
Results
160 pts completed the questionnaire (48% women, 52% men). The most common age groups were 51-65 years old (37%) and 66-80 years old (41%). The majority of pts are unemployed (58.5%). About half of interviewed pts undergo infusion therapies and/or visit 1-2 times monthly. When asked to describe the wait duration, approximately half found it long (32%) or too long (17%). Pts spend this period on mobile phones (47%), watching TV (21%), reading or listening to music (16%), and conversing with others (11%). Both positive (49% calm, 7.5% hopeful, 5% emotional involvement) and negative (26% boredom, 21% anxiety, 6% sadness, 5% anger, 1% apathy) emotions were experienced. The multiple logistic regression model confirms the independent predictor role for a negative emotional status in the WR of a perceived long or too long waiting period (OR=4.0, p<0.001) and the independent role of protector of male gender (OR=0.4, p0.008). A trend of significance emerged for employment (OR=0.4, p0.052) and engaging in active behaviors (OR=0.4, p0.058) as protective factors. When asked how to improve the quality of time in the WR, 38% suggested live entertainment (music, readings, and cancer information), 26% preferred access to newspapers and magazines. The most requested topics are treatment news (51%), diet (46%), and physical activity (27%).
Conclusions
For cancer pts the waiting can be a meaningful experience. Many pts find the wait long, boring, and anxiety-provoking. Our experience suggests how active and externalizing behaviors are less linked to negative emotions and interactive activities could improve the quality of time spent in the WR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11